Lifeline Therapeutics Completes $8 Million Private Placement

Lifeline Therapeutics, a health company dedicated to developing products that help people live better, healthier and longer lives by fighting oxidative damage in the body, announced the company completed an $8 million private placement. Keating Securities, LLC acted as sole placement agent of the financing. Proceeds from this funding will be used to eliminate the company's debt of $3 million, for U.S. research surrounding its Protandim product and as working capital related to the development of new antioxidant therapies.

()a href="http://home.businesswire.com/portal/site/biospace/index.jsp?epi-content=GENERIC&newsId=20050601006235&ndmHsc=v2*A1117105200000*B1117745095000*DgroupByDate*G2*J2*N1000122&newsLang=en&beanID=1229976837&viewID=news_view" target="_blank">BioSpace